Ask the Doctor: Is there any increased risk of FL transforming during watch and wait?
Boyu Hu, MD (University of Utah Health), discusses the increased risk of transformation in follicular lymphoma and its impact on treatment effectiveness.
News
LRF Welcomes Scientific Advisory Board Chair Sonali M. Smith, MD
LRF welcomes new SAB leadership and members Sonali M. Smith, MD of The University of Chicago (Chair); Ann S. LaCasce, MD, MMSc of Dana-Farber Cancer Institute (Chair-Elect); and Teresa Palomero, PhD of Columbia University (member)
Lymphoma Research Foundation Elects New Board of Director Leadership
Harriet Greenberg and Joel Pollick Joins Lymphoma Research Foundation Board of Directors
2021 Lymphoma Research Foundation Annual Gala and North American Educational Forum on Lymphoma To be Held Virtually
The Lymphoma Research Foundation (LRF) announced today that its premier fundraising event, the LRF Annual Gala, and patient education program, the North American Educational Forum on Lymphoma, will be held virtually in response to the continuing COVID-19 pandemic. The LRF…
Meet the 2021 Career Development Award and Postdoctoral Fellowship Grantees
The LRF Clinical Investigator Career Development Award (CDA) and Postdoctoral Fellowship Grant Program support junior faculty members and PhD and advanced clinical fellows pursuing research in lymphoma and chronic lymphocytic leukemia (CLL).
Read the Latest Issue of Pulse: Spring 2021
Pulse is a publication of the Lymphoma Research Foundation, providing the latest updates on the Foundation and its focus on lymphoma and chronic lymphocytic leukemia (CLL) research, awareness and education.
Paving the Way for Innovation
Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.
An Enduring Legacy of Hope and Impact
Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.
U.S. Food and Drug Administration Approves Loncastuximab Tesirine-lpyl for Large B-cell Lymphoma
Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Ask the Doctor: How can we determine the efficacy of the COVID-19 vaccine and how we may respond?
As the rollout of the new COVID-19 vaccines continues, there is constant new data related to the vaccines and their effects on individuals. While most of this data is preliminary, information related to the efficacy and effect of the vaccine…